DKP
ESPR

Davidson Kempner Partners’s Esperion Therapeutics ESPR Stock Holding History

Davidson Kempner Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$354K Buy
+222,482
New +$1.15M 0.01% 211

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Davidson Kempner Partners's ESPR Position: Q1 2023 in Review

Davidson Kempner Partners opened a new position in Esperion Therapeutics (ESPR) in Q1 2023: 222,482 shares worth $354K. The stake represents 0.01% of the portfolio and ranks #211 among its holdings.

164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • Davidson Kempner Partners held 222,482 shares of Esperion Therapeutics worth $354K as of Q1 2023.
  • Esperion Therapeutics was a new Davidson Kempner Partners position in Q1 2023.
  • Esperion Therapeutics made up 0.01% of Davidson Kempner Partners's portfolio in Q1 2023, its #211 holding.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on Davidson Kempner Partners's 13F filing for Q1 2023, filed 15 May 2023.